{"id":825160,"date":"2025-03-13T02:03:28","date_gmt":"2025-03-13T06:03:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nyxoah-reports-fourth-quarter-and-financial-year-2024-financial-and-operating-results\/"},"modified":"2025-03-13T02:03:28","modified_gmt":"2025-03-13T06:03:28","slug":"nyxoah-reports-fourth-quarter-and-financial-year-2024-financial-and-operating-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nyxoah-reports-fourth-quarter-and-financial-year-2024-financial-and-operating-results\/","title":{"rendered":"Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating Results"},"content":{"rendered":"
\n

\n REGULATED INFORMATION<\/strong>\n <\/p>\n

\n Nyxoah <\/strong>
\n Reports<\/strong>
\n Fourth<\/strong>
\n Quarter <\/strong>
\n and <\/strong>
\n Financial<\/strong>
\n Year\u00a0<\/strong>
\n 202<\/strong>
\n 4<\/strong>
\n Financial<\/strong>
\n and Operating<\/strong>
\n Results<\/strong>
\n
\n FDA PMA Application Review <\/em>
\n Nearing<\/em>
\n Conclusion<\/em>
\n
\n Positioned for U.S. Commercial Launch in<\/em>
\n March<\/em>
\n 2025<\/em>\n <\/p>\n

\n Mont-Saint-Guibert, <\/strong>
\n Belgium \u2013<\/strong>
\n March <\/strong>
\n 1<\/strong>
\n 3<\/strong>
\n , <\/strong>
\n 2024<\/strong>
\n , <\/strong>
\n 7<\/strong>
\n :<\/strong>
\n 0<\/strong>
\n 0<\/strong>
\n am <\/strong>
\n CET \/ <\/strong>
\n 2<\/strong>
\n :<\/strong>
\n 0<\/strong>
\n 0<\/strong>
\n am <\/strong>
\n ET<\/strong>
\n \u2013 Nyxoah<\/strong>
\n SA (<\/strong>
\n Euronext Brussels\/Nasdaq<\/strong>
\n : NYXH)<\/strong> (\u201cNyxoah\u201d or the \u201cCompany\u201d), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the fourth quarter and financial year 2024.\u00a0\u00a0 <\/p>\n

\n
\n Recent <\/strong>
\n Financial and Operating Highlights<\/strong>
\n <\/span>\n <\/p>\n